Heinz Läubli

42PUBLICATIONS
197CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jun 29, 2026
The evolving role of cytokines for CAR-T cell manufacturing and beyond.

|Jun 16, 2026
Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer.

|Jun 05, 2026
Cytotoxic CD39+ tumor-associated NK cells respond to NKG2A blockade in lung cancer.

|Feb 09, 2026
Cell Therapies and Bispecific Engagers: Redefining Strategies against Checkpoint Resistance.

Heinz Läubli, David König, Marco Donia

|Nov 19, 2025
A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma.

Silvia Guglietta, Anne Bärenwaldt, Anthony Sonrel

|Nov 11, 2025
Increase of Inhibitory Siglec receptors on T cells mitigates severe immune reactions during acute viral infections.

Natalia Rodrigues Mantuano, Anne Bärenwaldt, Mirza Sarcevic

Pageof 7

Frequent Collaborators

12 joint publications

Alfred Zippelius

6 joint publications

Marcel Trefny

4 joint publications

Matthias S Matter

4 joint publications

Nicole Kirchhammer